Antivirals (HIV protease inhibitors)
- Block viral polyprotein processing
- Darunavir is the dominant modern PI
- Often boosted with ritonavir/cobicistat
- High resistance barrier is clinically useful
- Major CYP3A interaction burden
- Metabolic/GI adverse effects are common
- Useful in selected resistant-treatment settings
Class at a glance
- Block viral polyprotein processing
Practical pearls
- Darunavir is the dominant modern PI
Pharmacology
- Major CYP3A interaction burden
Clinical role
- Often boosted with ritonavir/cobicistat
- High resistance barrier is clinically useful
- Useful in selected resistant-treatment settings
Safety / monitoring
- Metabolic/GI adverse effects are common
Self-check
- How does Antivirals (HIV protease inhibitors) work?
Block viral polyprotein processing. - Which HIV protease inhibitor is the dominant modern agent?
Darunavir.
Drugs in this class (7)
Antivirals (HIV protease inhibitors) prescription history
Animated chart of estimated U.S. prescriptions per year, HIV antiretrovirals (1987–2026). Protease inhibitors highlighted from 1996.
All drug classes · Open Antivirals (HIV protease inhibitors) in the interactive console ↗